OmniCyte Founder, Peter Leonardi, provides insight into the emerging field of immunotherapy. Immunotherapy is the…
This is Part I of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.
In this special series, we explore the state of select public companies operating in a particularly intriguing area of life sciences. This week, we look at metastatic cancer, an area of significant unmet need. These companies, including OncoSec Medical, are having success with their innovative approaches to treating metastatic cancer, and are seeing results in their performance int he public markets.
OneMedPlace introduces a new series, “The Briefing Room”, capturing the most important developments in microcap life sciences indexes. This week, we focus on three interesting developments in oncology, and a special bonus!
Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.
In a study of 19 patients with glioblastoma, progression-free survival increased from 6 months to 19 months.
The company’s vaccine technology is based on the universal tumor antigen, which has been expressed in all human cancers studied so far.
The idea of using harmful bacteria to treat disease might strike many as an odd concept.